Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients
- PMID: 3778112
- DOI: 10.1001/archpsyc.1986.01800120048010
Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients
Abstract
The relationship between dopamine receptor agonist (apomorphine hydrochloride)-stimulated growth hormone (GH) release and psychotic symptoms was examined in 138 schizophrenic or schizoaffective inpatients (Research Diagnostic Criteria) and ten healthy normal volunteers. Patients were divided into three groups: those demonstrating an abnormally large GH response, an average GH response (mean GH response), or an abnormally low GH response. Abnormally large GH responses were associated with higher total psychosis scores. The increased psychosis scores observed in this group were due primarily to an increased incidence of thought disorder. Further analysis revealed a strong, positive correlation between thought disorder and the GH response. The apomorphine-stimulated GH response was also significantly related to duration of illness, an effect independent of age. Consistent with this last result, patients with a diagnosis of a DSM-III schizophreniform disorder demonstrated an elevated GH response.
Similar articles
-
Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.Arch Gen Psychiatry. 1984 May;41(5):512-9. doi: 10.1001/archpsyc.1984.01790160098013. Arch Gen Psychiatry. 1984. PMID: 6721674
-
Growth hormone response to apomorphine and diagnosis: a comparison of three diagnostic systems.Biol Psychiatry. 1986 May;21(5-6):445-54. doi: 10.1016/0006-3223(86)90186-1. Biol Psychiatry. 1986. PMID: 3697435
-
Biological studies of DSM-III psychotic disorders. I. Platelet measures and apomorphine-induced growth hormone response.J Nerv Ment Dis. 1982 Dec;170(12):758-65. doi: 10.1097/00005053-198212000-00007. J Nerv Ment Dis. 1982. PMID: 6754871 Review.
-
Noradrenergic and dopaminergic interrelation in schizophrenia.Psychiatry Res. 1994 Sep;53(3):231-42. doi: 10.1016/0165-1781(94)90052-3. Psychiatry Res. 1994. PMID: 7870845 Clinical Trial.
-
Schizoaffective disorders are psychotic mood disorders; there are no schizoaffective disorders.Psychiatry Res. 2006 Aug 30;143(2-3):255-87. doi: 10.1016/j.psychres.2005.08.012. Epub 2006 Jul 20. Psychiatry Res. 2006. PMID: 16857267 Review.
Cited by
-
Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses.Br J Clin Pharmacol. 2001 Apr;51(4):317-24. doi: 10.1046/j.1365-2125.2001.01352.x. Br J Clin Pharmacol. 2001. PMID: 11318766 Free PMC article.
-
Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia.Neuropsychopharmacology. 2010 Nov;35(12):2462-78. doi: 10.1038/npp.2010.129. Epub 2010 Aug 25. Neuropsychopharmacology. 2010. PMID: 20736993 Free PMC article.
-
All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.CNS Neurosci Ther. 2011 Apr;17(2):118-32. doi: 10.1111/j.1755-5949.2010.00162.x. CNS Neurosci Ther. 2011. PMID: 20560996 Free PMC article.
-
The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.Drugs R D. 2018 Jun;18(2):91-107. doi: 10.1007/s40268-018-0230-3. Drugs R D. 2018. PMID: 29546602 Free PMC article. Review.
-
Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.Psychopharmacology (Berl). 1989;99 Suppl:S18-27. doi: 10.1007/BF00442554. Psychopharmacology (Berl). 1989. PMID: 2682729 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
